⌕
Integra Lifesciences Holdings · IART · Nasdaq
Tenet 41 · Weak
Compare
$13.98−2.92%At closeTenet 41 · Weak
$13.98−0.42 (−2.92%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Integra Lifesciences Holdings (IART) Earnings Forecast

Analysts expect Integra Lifesciences Holdings (IART) to earn $2.33 a share in FY26, the average of 7 estimates as of Nov 13, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

2 figures withheld by our checks. Each blank figure names its reason.

FY26 consensus EPS
$2.33
7 analysts
FY27 consensus EPS
$2.37
7 analysts · low $2.30, high $2.45
EPS revisions, 7 days
0.0%
$2.33 to $2.33
Disagreement, FY26
0.9%
high to low, $2.32 to $2.34

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 13, 2026 · we check it nightly

Analysts expect Integra Lifesciences Holdings to earn $3.00 a share in FY29, growing about 9% a year; 1 analyst publishes an estimate for FY29.

Forward P/E · FY26E
6.2×
$14.40 (as of close, Nov 13, 2026) ÷ $2.33 consensus EPS
Coverage · FY26
7 · 8
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $2.33, up 0.0% in 90 days, on the 7 days of it our record holds. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−1.0%+0.0%+1.0%FY26 +0.0%FY27 +0.0%Nov 6Nov 13
EPS30 days90 daysshown above
FY267 analysts7 of 30 days0.0% so far7 of 90 days0.0% so far
FY277 analysts7 of 30 days0.0% so far7 of 90 days0.0% so far
Sep '267 analysts7 of 30 days0.0% so far7 of 90 days0.0% so far
Dec '267 analysts7 of 30 days0.0% so far7 of 90 days0.0% so far

Contributors at both ends of the window: FY26 7 and 7. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 13, 2026 · consensus as of Nov 13, 2026

Pick a fiscal year and a multiple and the sum runs on the numbers the Street published.

Consensus EPS · FY27
$2.37
7 analysts · low $2.30, high $2.45 · thin coverage
Multiple · yours
We hold no multiple of our own for this company, neither today's nor a fiscal-year record, so the multiple can only be yours.
Receipt · IART · FY27Nov 13, 2026
Implied, a share
Waiting

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

You are paying 6.2 times the FY26 consensus for earnings the Street expects to grow about 3% a year to FY28. That is 2.2 times the growth rate.

How much do analysts disagree?

For FY29, estimates run from $2.97 to $3.04 around an average of $3.00, drawn by 1 analyst.

FY26E7 analysts
$2.32 to $2.34 · 0.9%
FY27E7 analysts
$2.30 to $2.45 · 6.3%
FY28E3 analysts
$2.00 to $2.94 · 37.9%
FY29E1 analyst
$2.97 to $3.04 · 2.4%

The dashed line is FY25 filed $−6.74, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average.

Is next quarter a high bar or an easy one?

Analysts expect Integra Lifesciences Holdings to earn $0.64 a share in the December quarter, the average of 7 estimates. We hold no expected date for the next report. Last quarter, which ended in September, Integra Lifesciences Holdings lost $0.07 a share. Analysts had expected $0.43, so it came in 116.1% lower.

0
$−0.03
$0.64high $0.75
low $0.60
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 7 analysts
Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
$422.4M
6 analysts, 422.0 to 422.8 in $M · 434.9 in the same quarter a year ago

A year ago this quarter was a loss, so the change from it is not a percentage and none is printed. Last quarter's comparison is measured against the last estimate we hold for that quarter rather than the one from the night before the report, because the nearest estimate we hold for it was recorded after the company had already reported. For the March quarter, analysts expect $0.49 a share.

Does Integra Lifesciences Holdings usually beat or miss?

So far we have checked 1 quarter: the one that ended in September 2025, when Integra Lifesciences Holdings lost $0.07 a share against the $0.43 analysts expected, 116.1% lower. We add a quarter to this record each time Integra Lifesciences Holdings reports.

We started recording estimates on Nov 6, 2026, so quarters that reported before that date cannot be checked.

Before our record
Dec '23
Our record, one quarter per report
Mar '24left out · adjusted
Jun '24left out · adjusted
Sep '24left out · adjusted
Dec '24left out · adjusted
Mar '25left out · adjusted
Jun '25left out · basis
−116.1%
Sep '25reaction
no closing prices
Dec '25left out · adjusted
Mar '26left out · adjusted
Jun '26left out · adjusted
Sep '26left out · adjusted
Dec '26not reported yet
Checked so far
1 quarter
one more every report
Beat expectations
0 of 1
full details on the Earnings tab
Share price reaction
Not held
we hold no closing prices around the release
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Integra Lifesciences Holdings on Nov 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact. Sep '25 is drawn hollow: we hold no estimate for that quarter recorded strictly before the report, so it is scored against the last estimate we hold rather than the night-before one.

The Street expects sales to grow 1.9% in FY27 and EPS 1.5%. Sales do all of it and the other two take some back: the net margin moves from 10.9% to 11.1%, and the implied share count from about 76.8M to 78.3M, so these numbers assume no buyback.Show the decomposition and the margin ladderHide the decomposition
FY27 EPS growth, in points
Revenue growth+1.9
Net margin change+1.7
Share count change−2.1
EPS growth+1.5
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
7 analysts publish an EPS estimate for FY26 and 8 publish revenue. Coverage thins with distance: 1 EPS estimate for FY29. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
87
FY26E
87
FY27E
83
FY28E
61
FY29E
The FY26 panel has held 7 analysts every night since our record of it began on Nov 6, 2026.

The full consensus, year by year

Consensus as of Nov 13, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
1.51.71.8historyStreet forecastFY22FY25FY29E

Coverage thins with distance: 8 revenue estimates for FY26, 6 for FY29.

Diluted EPS · $filed · consensus average · band = low to high
−7.33−1.953.43historyStreet forecastFY22FY25FY29E

Out-year bands widen as fewer analysts publish: 7 EPS estimates for FY26, 1 for FY29.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed1.6—−6.74————as filed87.0×
FY26E1.61.6 to 1.7▲0.5%a2.332.32 to 2.34n/ca0.40.20.088 · 76.2×
FY27E1.71.7 to 1.7▲1.9%2.372.30 to 2.45▲1.5%0.40.20.088 · 76.1×
FY28E1.71.7 to 1.8▲3.5%2.472.00 to 2.94n/cb0.40.20.088 · 35.8×
FY29E1.81.8 to 1.8▲4.2%3.002.97 to 3.04n/cb0.50.20.086 · 14.8×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 7 EPS estimates for FY26, 8 for revenue. Not investment advice.

What do analysts expect Integra Lifesciences Holdings to earn in FY26?

Analysts expect Integra Lifesciences Holdings to earn $2.33 a share in FY26, the average of 7 estimates as of Nov 13, 2026.

What is Integra Lifesciences Holdings' earnings forecast for FY27?

The FY27 consensus for Integra Lifesciences Holdings is $2.37 a share from 7 analysts, with a low of $2.30 and a high of $2.45, as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.